Heron Therapeutics, Inc. (NASDAQ:HRTX) Files An 8-K Financial Statements and Exhibits
Item 9.01
HERON THERAPEUTICS, INC. /DE/ Exhibit
EX-99.1 2 d675951dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 FDA Grants Priority Review Designation for Heron Therapeutics NDA for HTX-011,…
To view the full exhibit click here
About Heron Therapeutics, Inc. (NASDAQ:HRTX)
Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company’s SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.